



Sixth Annual
*Orlando Breast
Cancer Conference*

Chairman:

Hyman B. Muss, MD
Professor of Medicine
University of Vermont School
of Medicine

Co-Chairs:

Olufunmilayo I. Olopade, MD
Professor of Medicine
University of Chicago
Pritzker School of Medicine

Mark D. Pegram, MD
Professor of Medicine
University of Miami
Miller School of Medicine
Slyvester Comprehensive Cancer Center

John Pippen, Jr., MD, FACP
Attending Physician
Chair, Breast Tumor Site Committee
Baylor-Sammons Cancer Center

February 7 - 8, 2009

**Rosen Shingle Creek Resort,
Orlando, Florida**

Register Today At:

www.OrlandoBreastCancer.com

This activity is sponsored by:



MEDICAL EDUCATION CONFERENCES

Developing Medical Paradigms Through Education™

Orlando Breast Cancer Conference

Description

Despite recent advances in early detection and therapy for breast cancer, many patients have a poor prognosis, particularly those with metastatic disease. Newer methods for detection and selection of optimal therapy are needed, along with improved, less toxic drugs and regimens. This symposium will provide practicing oncologists with updates on recent advances and current challenges in the diagnosis and treatment of breast cancer. Leaders in the field will present in-depth presentations covering the use of hormonal therapy, radiation therapy, and chemotherapy. The current status of novel agents and emerging therapies will be reviewed along with new methods for diagnosis and predicting response to therapy.

Target Audience

Medical, surgical, and radiation oncologists, as well as other healthcare professionals involved in the research and treatment of patients with breast cancer

Educational Objectives

After participating in this activity, physicians should be able to:

1. Identify new diagnostic tools for diagnosing breast cancer and predicting response to therapy.
2. Explain the results from recent trials of hormonal therapy and chemotherapy in the adjuvant setting and apply these to the care of your patients with breast cancer.
3. Identify new agents and regimens, and evaluate their safety and efficacy for treatment of metastatic disease.
4. Summarize the New Data on Prevention and Genetics.
5. Identify and Explain the appropriate uses of Biologic Agents and Growth Factors
6. Explain what Role that Nanotechnology provides in the Diagnosis and Treatment of Breast Cancer.
7. Explain the Sexual Function Treatment Interventions available to breast cancer patients.
8. Define the Role of Localized Breast Radiation after Lumpectomy.
9. Identify and Explain the Role of Predictive Assays in Determining the Role of Chemotherapy in ER+/-HER2 Negative Patients.

Accreditation Statement

Medical Education Conferences, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

Medical Education Conferences, Inc. designates this educational activity for a maximum of 10 AMA PRA Category 1 credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Faculty Disclosure Statement

All faculty participating in continuing education activities sponsored by Medical Education Conferences, Inc. are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.





Orlando Breast Cancer Conference



INVITED FACULTY

E. Claire Dees, MD

Associate Professor
Clinical Research
Hematology/Oncology
UNC Lineberger Comprehensive Cancer Center

Charles E. Geyer, Jr., MD

Director of Medical Affairs
Medical Director, Foundation Research Program
National Surgical Adjuvant Breast and Bowel Project

William Gradishar, MD

Professor of Medicine
Feinberg School Medicine at
Northwestern University
Director of Breast Medical Oncology,
Associate Director of the
Lynn Sage Comprehensive Breast Program,
and Program Director of
Northwestern University's Hematology/Oncology
Fellowship Training Program

Claudine Isaacs, MD

Associate Professor of Medicine and Oncology
Director of Clinical Breast Cancer Program
Lombardi Comprehensive Cancer Center at
Georgetown University

Gary H. Lyman, MD, MPH, FRCP (Edin)

Editor-In-Chief, Cancer Investigation
Director, Health Services and
Outcomes Research Program-Oncology
Senior Fellow, Duke Center for
Clinical Health Policy Research
Duke University Medical Center

Hyman B. Muss, MD

Symposium Chairman
Professor of Medicine
Vermont Cancer Center
University of Vermont

Olufunmilayo I. Olopade, MD, FACP

Symposium Co-Chair
Professor of Medicine & Human Genetics
Director, Center for Clinical Cancer Genetics
The University of Chicago

Mark D. Pegram, MD

Symposium Co-Chair
Professor of Medicine
University of Miami
Miller School of Medicine
Slyvester Comprehensive Cancer Center

John Pippin Jr., MD, FACP

Symposium Co-Chair
Attending Physician
Chair, Breast Tumor Site Committee
Baylor-Sammons Cancer Center

Leslie R. Schover, PhD

Professor
Department of Behavioral Science
The University of Texas
M.D. Anderson Cancer Center

Don Weaver, MD

Professor of Pathology
Vermont Cancer Center
University of Vermont

Jennifer L. West, PhD

Professor
Howard Hughes Medical Institute
Isabel C. Cameron Professor of Bioengineering
Rice University

Timothy Whelan, BM, BCh, FRCP

Professor, Department of Medicine and
Department of Clinical Epidemiology & Biostatistics
McMaster University
Juravinski Cancer Centre

Marie E. Wood, MD

Professor of Medicine
Director of Familial Cancer Program
Vermont Cancer Center
University of Vermont

Orlando Breast Cancer Conference

AGENDA

Saturday, February 7, 2009

7:00 – 8:00 am Registration and Breakfast

Session I: Prevention, Screening in the High Risk Patient, & Radiation Therapy

Moderator: Funmi Olopade

8:00 – 8:05 am	Introduction	
8:05 – 8:25 am	Update on Prevention	Marie Wood
8:25 – 8:45 am	Genes, Genomics and Breast Cancers	Funmi Olopade
8:45 – 9:05 am	Localized Breast Radiation after Lumpectomy	Timothy Whelan
9:05 – 9:25 am	Breast Pathology in the Genomic Era	Don Weaver
9:25 – 9:40 am	Case Discussions - attendees and faculty	Funmi Olopade
9:40 – 10:00 am	Break	

Session II: Adjuvant Treatment of Early Breast Cancer

Moderator: Hyman Muss

10:00 – 10:20 am	Hormone Therapy in Pre-Menopausal Women	Claudine Isaacs
10:20 – 10:40 am	Hormonal Therapy in Post-Menopausal Women	Hyman Muss
10:40 – 11:00 am	Adjuvant Therapy for HER2 Positive Patients	Mark Pegram
11:00 – 11:20 am	Chemotherapy for Triple Negative Tumors	Funmi Olopade
11:20 – 12:00 pm	Case Discussions - attendees and faculty	Hyman Muss
12:00 – 1:00 pm	Lunch	
1:00 – 1:20 pm	Predictive Assays for ER Positive Low Risk Patients	Hyman Muss
1:20 – 1:40 pm	Chemotherapy for ER+/Node Positive/HER2 Negative Patients	Mark Pegram
1:40 – 2:20 pm	Case Discussions - attendees and faculty	Hyman Muss

Sunday, February 8, 2009

7:00 – 8:15 am Registration and Breakfast

7:30 – 8:15 am Case-Study on Metastatic Breast Cancer
Session Co-Chairs:

Hyman Muss, Mark Pegram

Session III: Metastatic Breast Cancer

Moderator: Mark Pegram

8:30 – 8:55 am	Chemotherapy in Metastatic Breast Cancer	William Gradishar
8:55 – 9:20 am	Biologic Agents in the Metastatic Setting	Charles Geyer
9:20 – 9:45 am	Case Discussions - attendees and faculty	Mark Pegram
9:45 – 10:05 am	Break	

Session IV: Hot Topics

Moderator: Hyman Muss

10:05 – 10:35 am	Update on Growth Factors	Gary Lyman
10:35 – 11:05 am	Survivorship Issues in Breast Cancer Patients	Claire Dees
11:05 – 11:35 am	Sexuality and Breast Cancer	Leslie Schover
11:35 – 12:05 pm	Case Discussions - attendees and faculty	Hyman Muss
12:05 – 12:35 pm	Symposium Closing Remarks	